Calmare Therapeutics Stock Net Income
| CTTCDelisted Stock | USD 0.0001 0.00 0.00% |
Calmare Therapeutics fundamentals help investors to digest information that contributes to Calmare Therapeutics' financial success or failures. It also enables traders to predict the movement of Calmare Stock. The fundamental analysis module provides a way to measure Calmare Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Calmare Therapeutics stock.
Calmare |
Calmare Therapeutics Company Net Income Analysis
Calmare Therapeutics' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Calmare Therapeutics Net Income | (3.83 M) |
Most of Calmare Therapeutics' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Calmare Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
CompetitionBased on the recorded statements, Calmare Therapeutics reported net income of (3.83 Million). This is 101.12% lower than that of the Health Care Equipment & Supplies sector and 101.61% lower than that of the Health Care industry. The net income for all United States stocks is 100.67% higher than that of the company.
Calmare Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Calmare Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Calmare Therapeutics could also be used in its relative valuation, which is a method of valuing Calmare Therapeutics by comparing valuation metrics of similar companies.Calmare Therapeutics is currently under evaluation in net income category among its peers.
Calmare Fundamentals
| Return On Asset | -0.38 | |||
| Operating Margin | (2.14) % | |||
| Current Valuation | 11.54 M | |||
| Shares Outstanding | 30.38 M | |||
| Shares Owned By Institutions | 6.92 % | |||
| Number Of Shares Shorted | 212.63 K | |||
| Price To Earning | (0.68) X | |||
| Price To Sales | 4.82 X | |||
| Revenue | 1.17 M | |||
| Gross Profit | 771.48 K | |||
| EBITDA | (2.43 M) | |||
| Net Income | (3.83 M) | |||
| Cash And Equivalents | 12.55 K | |||
| Current Ratio | 0.22 X | |||
| Book Value Per Share | (0.48) X | |||
| Cash Flow From Operations | (1.24 M) | |||
| Short Ratio | 3.99 X | |||
| Earnings Per Share | (0.13) X | |||
| Target Price | 0.79 | |||
| Beta | 0.57 | |||
| Market Capitalization | 11.09 K | |||
| Total Asset | 3.88 M | |||
| Retained Earnings | (62.01 M) | |||
| Working Capital | (12.68 M) | |||
| Current Asset | 3.96 M | |||
| Current Liabilities | 16.64 M | |||
| Z Score | -24.6 | |||
| Net Asset | 3.88 M |
About Calmare Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Calmare Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Calmare Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Calmare Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Other Consideration for investing in Calmare Stock
If you are still planning to invest in Calmare Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Calmare Therapeutics' history and understand the potential risks before investing.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |